Loading
A phase 1/2 trial of 23ME-00610 in renal cell carcinoma, ovarian cancer, neuroendocrine tumours and small-cell lung cancer, run by 23andMe, Inc., active and no longer recruiting.
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT05199272 by 23andMe, Inc., with 141 participants enrolled, started 2021-12-29 and due to reach its primary completion in 2025-03. Interventions recorded: 23ME-00610.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ovarian cancer, Small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Small-cell lung cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/